Sort
10,766 grants matching “checkpoint inhibitor”
Targeting the Mitochondria to Overcome Resistance to Immune Checkpoint Inhibition in Malignant Pleural Mesothelioma
$659,626Robert Taylor Ripley · Baylor College Of Medicine · R37 · FY2025 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression
$659,220Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2023 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression
$659,220Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2022 · CA
Mutant KRAS targeted vaccines for the interception of pancreatic cancer development
$659,090Neeha Zaidi · Johns Hopkins University · R37 · FY2025 · CA
Mutant KRAS targeted vaccines for the interception of pancreatic cancer development
$659,090Neeha Zaidi · Johns Hopkins University · R37 · FY2024 · CA
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
$659,051Manish Bais · Boston University Medical Campus · R01 · FY2023 · DE
Molecular, Cellular and Genetic Analyses of Malignancies Associated with NF1
$659,046Karlyne M Reilly · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Epigenetic Therapy for Thoracic Malignancies
$658,967David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2020 · CA
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local Immunotherapy
$658,892Simon Young · University Of Texas Hlth Sci Ctr Houston · R01 · FY2023 · DE
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy
$658,891Youngho Seo · University Of California, San Francisco · R01 · FY2025 · HL
Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$658,720David E Fisher · Massachusetts General Hospital · P01 · FY2024 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
$658,454Michelle S Bradbury · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
Biological and social determinants of psychosocial sequelae in advanced head and neck cancer survivors receiving immunotherapy
$658,403Canhua Xiao · Emory University · R01 · FY2025 · CA
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity
$658,369David G Denardo · Washington University · U01 · FY2023 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer
$658,205Jia Wu · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
$657,955Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2019 · CA
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
$657,944Calvin J Kuo · Stanford University · R01 · FY2021 · CA
Generation of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivation
$657,791Cheryl A London · Tufts University Boston · U01 · FY2023 · CA
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor
$657,573David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Targeting natural killer cells to enhance HIV vaccine responses
$657,254Stephen N. Waggoner · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · AI
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer
$657,132Dohun Pyeon · Michigan State University · R01 · FY2021 · DE
Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events
$657,119Aung Naing · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events
$657,119Aung Naing · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
$657,074Lan Zhou · Methodist Hospital Research Institute · R01 · FY2025 · CA
Mechanisms of Nucleic Acid Enzymes - Pol Beta, HIV-1 Reverse Transcriptase and Mammalian Base Repair Enzymes
$657,042Samuel H Wilson · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES